BioBeats Resend And Our Most Read Reports

Research evidence excerpt

BioBeats Resend And Our Most Read Reports

Biotechnology

EQUITY RESEARCH Industry Report

June 28, 2026

Research Analysts:

Steve Seedhouse Cantor's Biopharma team has added 30 stocks to our collective coverage

212-915-1240

Steve.Seedhouse@cantor.com list so far in 2026 through the halfway point (including 4 more this week).

Josh Schimmer These new ideas are of course in addition to our unyielding cadence of

310-282-6513 proprietary work and differentiated access (also all present in spades in this

Josh.Schimmer@cantor.com week's BioBeats - so check it out).

Eric Schmidt

212-294-7724 Click HERE for the link to Friday's BioBeats recording or open this report

Eric.Schmidt@cantor.com for the slides.

Prakhar Agrawal

212-610-3614

Prakhar.Agrawal@cantor.com BioBeats Trivia Answer: Definium posted positive P3 MDD data for LSD.

Olivia Brayer Saunders

212-428-5907 ●What was Definium previously known as? MindMed

Olivia.Brayer@cantor.com ●What tech visionary credited his LSD experiences as “one of the two or

Carter Gould three most important things” he had done in his life? Steve Jobs 212-915-1794

Carter.Gould@cantor.com ●What Nobel Laureate credited LSD for his inventing of PCR? Kary Mullis

Kristen Kluska

212-915-1927 Ahead Next Week:

Kristen.Kluska@cantor.com

●Monday, 6/29 @ 10AM: Cantor hosting "Cantor Catalysts" Webinar Imogen Mansfield

929-545-6495 with PHVS to Preview Phase 3 HAE Data (register HERE)

Imogen.Mansfield@cantor.com

●Tuesday 6/30 - Wednesday 7/1: Cantor hosting ALMS NDR in London/ Yanni Souroutzidis

929-730-2656 Zurich

Yanni.Souroutzidis@cantor.com

Pete Stavropoulos, Ph.D. This Week's Most Read Reports:

212-915-1966

Pete.Stavropoulos@cantor.com ●BioBUZZ - Sunshiny Day (HERE) / BioBUZZ - Up, Up and Away (HERE)

Li Watsek

212-915-1221 ●BioBeats - We're Cooking (HERE)